NVAX · Novavax Inc
$9.07
+0.65 (+7.72%)
At close · Aug 21
Market Cap
$1.45B
Shares
164.95M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.42
Open$8.50
Day$8.02–8.66
52W close$6.22–11.19
Avg vol 30d3.5M
Short int45.7M · 27.7% float · 16.6d
Short vol45%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 6, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−0%
below
Price vs 50-day avg
−0%
below
RSI (14)
56
neutral
MACD trend
Positive
52-week position
44%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+8%
trailing
6-month return
−17%
trailing
YTD return
+25%
this year
Relative strength
−28%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +41 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
27.68% of float · ▲ +4.2% MoM · 16.6 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
267 holders — near 3-yr high, broad support
Squeeze score
80
high risk · 0–100
Fundamentals
Revenue growth
+65%
Y/Y
EPS growth
+310%
Y/Y
Balance sheet
$4.0M
net debt
Quant / Vol
risk profile
Volatility
65%
annualized · 1-yr
Max drawdown
−35%
past year
ATR
4.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
Non-GAAP combined R&D and Selling, General and Administrative (S
· full year 2028
Non-GAAP
$150M – $200M
Prior guidance
period ended
· from the 8-K filed Jan 12, 2026
Combined R&D and SG&A Expenses, Net of Partner Reimbursement
· FY 2025 E
$250M
Guided vs delivered
· last 3 settled
Total revenue
2024
guided $400M – $600M
$682.16M
Beat +36.4%
Total revenue
first quarter 2024
guided $100M
$93.86M
Miss −6.1%
Total revenues
2023
guided $1B
$983.71M
Miss −1.6%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−0%
Neutral
Price vs 50-day avg
−0%
Neutral
RSI (14)
56
Neutral
MACD trend
Positive
Bullish
52-week position
44%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +41 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
27.68% of float · ▲ +4.2% MoM · 16.6 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
267 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $8 · 44%
Range high $11
vs 200-day avg 0%
vs 50-day avg 0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP R&D Expenses, net of partner reimbursement non-GAAP | $48M | Q2 2026 | — |
| Adjusted Total Revenue non-GAAP | $118.9M | Q1 2026 | — |
| Non-GAAP Combined R&D and SG&A Expenses non-GAAP | $96.6M | Q1 2026 | — |
| Non-GAAP R&D Expenses non-GAAP | $67.8M | Q1 2026 | — |
| Pfizer upfront payment | $30M | Q1 2026 | — |
| R21/Matrix-M malaria vaccine doses sold since launch | 30M | FY2025 | — |
| Sanofi milestones earned | $225M | FY2025 | — |
| Takeda Nuvaxovid market share in Japan | 12% | FY2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NVAX
this stock
Novavax Inc
|
$1.45B | +25.3% | +64.7% | — | 27.7% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NVAX | +3.4% | +7.5% | -17.0% | +15.0% | +25.3% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +5.4% | +4.2% | -28.1% | +13.0% | +13.5% |
Key facts
CIK
1000694
CUSIP
670002401
13F (30d)
266 filings
241 filers
Visit website
Investor relations